OppenheimerFunds’s Jazz Pharmaceuticals JAZZ Stock Holding History

OppenheimerFunds’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$17.7M	Sell	123,495 -1,873	-1%	-$244K	0.02%	566
2018 Q4	$15.5M	Buy	125,368 +14,690	+13%	+$2.18M	0.02%	568
2018 Q3	$18.6M	Sell	110,678 -7,060	-6%	-$1.21M	0.02%	602
2018 Q2	$20.3M	Sell	117,738 -20,895	-15%	-$3.42M	0.02%	576
2018 Q1	$20.9M	Sell	138,633 -12,221	-8%	-$1.79M	0.03%	555
2017 Q4	$20.3M	Sell	150,854 -58,116	-28%	-$8.06M	0.02%	576
2017 Q3	$30.6M	Buy	208,970 +4,080	+2%	+$617K	0.04%	439
2017 Q2	$31.9M	Buy	204,890 +54,050	+36%	+$8.27M	0.04%	420
2017 Q1	$21.9M	Buy	150,840 +52,960	+54%	+$6.9M	0.03%	550
2016 Q4	$10.7M	Hold	97,880	–	–	0.01%	745
2016 Q3	$11.9M	Sell	97,880 -14,500	-13%	-$1.95M	0.01%	700
2016 Q2	$15.9M	Buy	112,380 +49,500	+79%	+$7.3M	0.02%	624
2016 Q1	$8.21M	Buy	62,880 +890	+1%	+$111K	0.01%	752
2015 Q4	$8.71M	Sell	61,990 -2,460	-4%	-$341K	0.01%	762
2015 Q3	$8.56M	Sell	64,450 -13,050	-17%	-$2.25M	0.01%	751
2015 Q2	$13.6M	Buy	77,500 +18,650	+32%	+$3.35M	0.02%	685
2015 Q1	$10.2M	Buy	58,850 +2,980	+5%	+$511K	0.01%	752
2014 Q4	$9.15M	Buy	+55,870	New	+$9.27M	0.01%	781
2014 Q2	–	Sell	-171,916	Closed	-$23.8M	–	952
2014 Q1	$23.8M	Sell	171,916 -63,770	-27%	-$9.6M	0.03%	531
2013 Q4	$29.8M	Sell	235,686 -226,306	-49%	-$23.4M	0.04%	470
2013 Q3	$42.5M	Buy	461,992 +208,816	+82%	+$16.8M	0.03%	518
2013 Q2	$17.4M	Buy	+253,176	New	+$15.5M	0.03%	544

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

OppenheimerFunds's JAZZ Position: Q1 2019 in Review

OppenheimerFunds reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.5% in Q1 2019, selling an estimated $244K and leaving 123,495 shares worth $17.7M. The position accounts for 0.02% of the portfolio, ranked #566.

OppenheimerFunds first reported a position in JAZZ in Q2 2013 and has held it in 22 quarters since. The position peaked at $42.5M in Q3 2013. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

OppenheimerFunds held 123,495 shares of Jazz Pharmaceuticals worth $17.7M as of Q1 2019.
OppenheimerFunds sold 1,873 Jazz Pharmaceuticals shares in Q1 2019, an estimated $244K.
Jazz Pharmaceuticals made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #566 holding.
OppenheimerFunds first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
OppenheimerFunds's Jazz Pharmaceuticals position peaked at $42.5M in Q3 2013.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.